WO2009127825A1 - Topical combinations comprising an antimycotic agent and an antiviral agent - Google Patents

Topical combinations comprising an antimycotic agent and an antiviral agent Download PDF

Info

Publication number
WO2009127825A1
WO2009127825A1 PCT/GB2009/000975 GB2009000975W WO2009127825A1 WO 2009127825 A1 WO2009127825 A1 WO 2009127825A1 GB 2009000975 W GB2009000975 W GB 2009000975W WO 2009127825 A1 WO2009127825 A1 WO 2009127825A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
composition according
solution
agent
Prior art date
Application number
PCT/GB2009/000975
Other languages
French (fr)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Limited
Curtis, Philip, Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, Curtis, Philip, Anthony filed Critical Cipla Limited
Priority to BRPI0907317A priority Critical patent/BRPI0907317A2/en
Priority to AU2009237478A priority patent/AU2009237478A1/en
Priority to EP09732346A priority patent/EP2282777A1/en
Priority to CN200980113498XA priority patent/CN102006889A/en
Priority to JP2011504526A priority patent/JP2011518140A/en
Priority to CA2721457A priority patent/CA2721457A1/en
Priority to US12/988,155 priority patent/US20110104262A1/en
Priority to MX2010011244A priority patent/MX2010011244A/en
Publication of WO2009127825A1 publication Critical patent/WO2009127825A1/en
Priority to ZA2010/07309A priority patent/ZA201007309B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, in particular, for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.
  • STIs sexually transmitted infections
  • viral infections present a public health crisis.
  • STIs are asymptomatic and there is a high morbidity rate associated with untreated infections.
  • AIDS pandemic is a premiere public health concern. Individuals who are at high risk of HIV/ AID S infection are also at risk of infection by other sexually transmitted pathogens. Similarly, individuals at risk for non- HIV/AIDS sexually transmitted pathogens are also at high risk for HIV/ AIDS infection.
  • STIs cause acute and chronic infections, infertility, and in some cases, cancer.
  • Vaccines which are costly and time- consuming to develop, are not available for certain STIs such as HIV/AIDS prevention.
  • HIV/AIDS treatment employs therapeutic strategies, such as retrovirus triple therapy (e.g., AZT, DDI, etc.) to lower virus burden.
  • retrovirus triple therapy e.g., AZT, DDI, etc.
  • the high expense of treatment renders this therapeutic option practically unavailable to populations in developing countries where HIV/AIDS is most prevalent.
  • the sum of all available STI/ AID S therapeutics is effective against only a limited number of susceptible pathogens.
  • this limited therapeutic arsenal is largely confined to proprietary formulations, which are costly for the afflicted to procure.
  • Vaginal candidiasis is the most common form of vaginitis, occurring more frequently than trichophyton, chlamydia, gonorrhea, or other bacterial infections. It is estimated that 75% of women will experience at least one episode of vulvovaginal candidiasis in their lifetime. 40 to 50% will experience a second episode in their life-time. A much smaller (probably less than 5%), but still significant, number of women will suffer from repeated, often intractable attacks.
  • Candidiasis is known to increase the risk of HIV/AIDS acquisition.
  • BV Bacterial vaginosis
  • Gardnerella vaginitis is the most common cause of vaginal discharge. It may be the cause of up to 50% of cases of vaginitis in all women and from 10-30% in pregnant women.
  • BV is not a sexually transmitted disease although it is sometimes listed as one.
  • the risk of contracting the disease increases with multiple sex partners. Although treatment is available for these diseases, methods to prevent them and improved methods of treatment are still needed.
  • vaginal contraceptive compositions often containing nonoxynol-9 as an active ingredient, are generally known in the art. While presently marketed vaginal contraceptive formulations aid in preventing pregnancy, their ability to effectively prevent STIs, particularly HIV/ AIDS as well as oral, rectal and vaginal infections, is very limited. Nonoxynol-9 and other detergents as well as their compositions can destroy the natural and safe ecology of the vagina, such as by inactivating lactobacillus bacteria. Further, spermicides may cause vaginal irritation, particularly with frequent exposure or higher doses. Recent analyses show that nonoxynol-9, when used frequently by women at high risk, may increase the risk of HIV infection (WHO 2002, WHO/CONRAD technical consultation on nonoxynol-9, Geneva).
  • antiviral agents have been developed for the treatment of patients with human immunodeficiency virus (HIV) infection.
  • HIV human immunodeficiency virus
  • only temporary and limited benefits are observed in HIV-infected patients treated with any of the actual anti-retrovirals or combinations of them.
  • the limited ability of these agents to decrease viral burden, the rapid development of resistance and the toxic side-effects of most drugs has limited their long-term efficacy.
  • One major problem associated with the administration of antiviral agents to patients is their poor ability to penetrate and target infected cells. Rapid drug clearance and the toxicity of parent compounds or metabolites constitute also some of the major drawbacks which may slow down the development and use of many antiviral agents.
  • strategies aimed at reaching therapeutic levels of drags into infected cells and reducing toxicity should be explored.
  • US20050037033 discloses a microbicidal compositions containing Ciclopirox olamine for preventing the transmission of or treating sexually transmitted infections and/or common vaginal infections.
  • WO9602226 discloses a pharmaceutical composition comprising a combination of 1- hydroxy-2-pyridones such as Ciclopirox or Octopirox and Crotamiton as an antifungal agent activity enhancer.
  • WO9717075 discloses a topical foamable pharmaceutical composition of Ciclopirox or Ciclopirox olamine and surfactant for treating skin diseases induced by oval Pityrosporum.
  • US20050196418 discloses a composition comprising a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof.
  • US20050276836 discloses a vaginal device for delivering therapeutic and/or health- promoting agents, wherein said vaginal device is a vaginal tampon, vaginal tampon-like device, vaginal ring & others.
  • US 5,292,516 disclose process of treating a condition by means of application of in-situ gel formulations comprising poloxamers administered by means of medical device.
  • the object of the present invention is to provide a novel pharmaceutical composition, in particular, for prophylaxis and/or treatment of sexually transmitted infections including HIV/ AIDS and/or common vaginal infections which stands against resistant strains.
  • Another object of the present invention is to provide a novel composition, in particular, for prophylaxis and/or treatment of sexually transmitted infections including HIV/AIDS and/or common vaginal infections while rninimizing disruptions to vaginal ecology and epithelium without compromising the stability and efficacy of the formulation.
  • Yet another object of the present invention is to provide topical liposomal formulations of drugs for the treatment of sexually transmitted infections including HTV/ AIDS and/or related vaginal infections that result in an increased efficacy and reduced toxicity of antiviral agents in humans suffering from sexually transmitted infections including HTV and/or related vaginal infections.
  • Still another object of the present invention is to provide a novel pharmaceutical composition and/or medicament with ease of manufacture.
  • a novel pharmaceutical composition for topical administration comprising one or more antimycotics or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more anti-viral agent/s or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
  • a novel pharmaceutical composition for topical administration comprising Ciclopirox or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and Tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
  • a novel pharmaceutical composition for topical administration comprising liposome en-capsulated Tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof wherein the said liposomes allows high cellular penetration, good in vitro antiviral activity against HIV which in turn provides a marked improvement of the pharmacokinetics of drugs.
  • a process of manufacturing the said novel pharmaceutical composition for topical administration comprising Ciclopirox or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof; one or more anti-viral agent/s or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
  • a process of manufacturing the said novel pharmaceutical composition for topical administration comprising liposome encapsulated tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • a novel pharmaceutical composition for topical administration for prophylaxis and/or treatment of sexually transmitted infections including HIV/ AID S and/or related vaginal infections.
  • Any of the active materials described and claimed in this specification may be provided in the form of the free material or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • the inventors have surprisingly found that by incorporation of liposome en-capsulated Tenofovir in a suitable topical formulation (e.g. gel composition or spray foam) prevented the transmission of infectious pathogens and its permeation through the membrane of mucosa by means of physical cum pharmacological barrier thereby preventing infection of host cells.
  • a suitable topical formulation e.g. gel composition or spray foam
  • Liposomes are microscopic vesicles in which a variety of drugs can be incorporated, to form a non-toxic and biodegradable formulation because of the similarity of the primary components of liposomes with natural membranes. It allows high cellular penetration, efficient targeting of macrophage-rich tissues and a marked improvement in drug pharmacokinetics.
  • the liposomal topical formulation provides improved delivery of active agents to the infected cells and also reduces the toxic effects associated with their administration which in turn improved efficacy and safety of the drug used for the treatment of sexually transmitted infections including HIV/AIDS and/or related vaginal infections.
  • liposomes When applied locally to mucosa or skin, liposomes are usually taken up by monocytes and macrophages and also by Langerhans cells which may capture and harbor HIV. Consequently, in contrast with free drugs, which tend to diffuse rapidly through the mucosa and reach the circulation, the use of drugs within liposomes and incorporated into a topical formulation (e.g. gel formulation or spray foam) concentrates the active agents within infected cells as well as within cells susceptible to HIV infection.
  • a topical formulation e.g. gel formulation or spray foam
  • topical combination comprising ciclopirox and tenofovir (or liposome encapsulated tenofovir) exhibited excellent anti-infective activity against opportunistic infections encountered in STFs and/or AIDS, such as vaginal infections without compromising on the stability of the formulation.
  • the protection from sexually transmitted infections such as HIV/AIDS, and common vaginal infections, such as bacterial vaginosis and vaginal candidiasis, may be obtained by application of the novel pharmaceutical composition to vagina, rectum or other orifice.
  • compositions may be used alone or in conjunction with delivery and/or contraceptive devices or methods, such as mechanical barrier-type devices.
  • Pharmaceutical compositions, according to the present invention may be formulated in various dosage forms including a base or carrier, such as a foam, cream, wash, gel, suppository, ovule, lotion, ointment, film, foaming tablet, tampon, vaginal spray, or aerosol.
  • the novel pharmaceutical composition for topical administration may encompass one or more anti-infectives selected from the class of, but not limited to, antimycotics, antimycobacterials, antibacterials, antivirals or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • a novel pharmaceutical composition for topical administration may comprise antimycotics (e.g. Ciclopirox) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and Tenofovir (or liposome encapsulated Tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients for prophylaxis and/or treatment of STI 's including HTV/ AID S and related viral infections .
  • antimycotics e.g. Ciclopirox
  • pharmaceutically acceptable solvates e.g. Ciclopirox
  • pharmaceutically acceptable solvates e.g. Ciclopirox
  • pharmaceutically acceptable solvates e.g. Ciclopirox
  • pharmaceutically acceptable solvates e.
  • the novel pharmaceutical composition for topical administration may comprise one or more antimycotics selected from the class of, but not limited to ketoconazole, itraconazole, fluconazole, ravuconazole, posaconazole, voricnazole, caspofungin, hydroxypyridones derivatives such as ciclopirox, mimosine, deferipone or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof with one or more antiviral agents selected from the class of, but not limited to Tenofovir, Acyclovir and Ganciclovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
  • antimycotics selected from the class of, but not limited to ketoconazole, itraconazole, fluconazo
  • the pharmaceutical composition for topical administration may comprise liposome encapsulated tenofovir with one or more pharmaceutically acceptable excipients or combination of ciclopirox [or liposome encapsulated ciclopirox] or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof with tenofovir (or liposome encapsulated tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
  • the pharmaceutical formulations may be applied to the body cavities such as the vagina and rectum. It will be readily acknowledged to a person skilled in the art; that the formulation may also be applied to the skin and other mucous membranes.
  • the said novel pharmaceutical formulations inactivate bacteria, fungi and/or viruses, and are stable at ambient temperature, compatible and active after mixture with cosmetically acceptable formulations, non-toxic and non- damaging to vulvar, vaginal, cervical, penile or other epithelium.
  • the pharmaceutical composition of the present invention prevents the transmission of or treats sexually transmitted infections and/or common vaginal infections.
  • sexually transmitted infections include, but are not limited to, HIV/AIDS, herpes (caused by herpes simplex virus type 1 (HSV-I) or herpes simplex virus type 2 (HSV-2)), gonorrhea, Chlamydia, syphilis, and trichomoniasis.
  • Common vaginal infections include, but are not limited to, bacterial vaginosis (BV) and vaginal candidiasis. Similar compositions and methods of application of such compositions, as described herein, can be used for treating sexually transmitted infections and/or common vaginal infections and for preventing the transmission of sexually transmitted infections and/or common vaginal infections.
  • the present invention involves the topical application of the formulation.
  • topical application includes application to the body cavities as well as to the skin.
  • the formulation is applied to a body cavity such as the vagina, anus, rectum or mouth.
  • the composition is applied to the vagina.
  • the topical application is carried out prior to the beginning of vaginal intercourse, preferably from 0 to 8 hours, more preferably from 0 to 60 minutes.
  • the composition including the combination may be used independent from intercourse.
  • the pharmaceutically acceptable excipients may include, but are not limited to, one or more surfactant, emollient or humectant, pH adjusting agent, fatty alcohol, preservative, lipid core components (e.g. phospholipids), organic solvent, gelling agents, chelating agents, film forming polymers, antioxidants, propellants or combinations thereof based on the type/route of administration of the formulation.
  • the surfactants may be selected from, but not limited to, Polyoxyethylene alcohol, alkylphenol ethoxylate, polysorbate 80, polysorbate 60, polymethylsiloxane, alkylphenol ethoxylate, poloxomer 407, sorbitan nionostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, polyethylene glycol (PEG) stearic acid esters (e.g. polyethylene glycol 100 stearate).
  • PEG polyethylene glycol
  • Suitable humectants and/or emollients provide smoothness and lubricity which, in turn, facilitate the loading and dispensing of the formulation.
  • the emollients and/or humectants may be selected from, but not limited to, polyhydric alcohols such as glycols, and polysaccharides, such as ethylene glycol, propylene glycol, butylene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, sorbitol, malvitol, trehalose, raffinose, xylitol, mannitol, polyethylene glycol, propylene glycol, polyglycerin, cholesterol, squaline, fatty acids, octyldodecanol, myristyl alcohol, urea, lanolin, lactic acid, esters such as isopropyl stearate, isopropyl myristate, isopropyl
  • the pH adjusting agents may be selected from, but not limited to, lactic acid, sodium hydroxide, acetic acid, citric acid, tartaric acid, propionic acid, sodium phosphate, ammonia solution, triethanolamine, sodium borate, sodium carbonate, potassium hydroxide and like.
  • the fatty alcohols may be selected from, but not limited to, stearyl alcohol, cetyl alcohol, capryl alcohol, myristyl alcohol, 1-dodecanol, palitoleyl alcohol, oleyl alcohol, linoleyl alcohol, isostearyl alcohol and like, preferably stearyl alcohol and cetyl alcohol.
  • the preservatives may be selected from, but not limited to, benzyl alcohol, hydroxybenzoates (parabens), Benzoic Acid, Chlorphenesin, Sorbic Acid, Phenoxyethanol and like.
  • Lipid core components may be selected from, but not limited to, natural phospholipids such as egg yolk lecithin (phosphatidylcholine), soybean lecithin, lysolecithin, sphingomyelin, phosphatide acid, phosphatidylserine, phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, cardiolipin, plasmalogen, etc., or hydrogenation products obtainable from said phospholipids by the conventional technology (Hydrogenated soy phosphatidyl choline), and synthetic phospholipids such as dicetyl phosphate, distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidyl glycerol, distearoylphosphatidyl glycerol, dilaurylphosphati
  • lipids or their mixtures may further contain substances selected from dicetylphosphate, cholesterol, coprostanol, cholestanol, cholestane, ergosterol, phytosterol, sitosterol, lanosterol, protein (e.g.
  • albumin immunoglobulin, casein, insulin, hemoglobin, lysozyme, immunoglobulin, [alpha]-2-macroglobulin, fibronectin, vitronectin, fibrinogen, lipase, or enzyme) which strengthens the lipid and other additives like ⁇ -tocopherol, stearic acid, antioxidants, BHT (butylhydroxytoluene), ascorbic acid, deferoxime mesylate, stearyl amine and/or mixtures thereof.
  • BHT butylhydroxytoluene
  • gelling agents such as, alginic acid, sodium alginate, potassium alginate, agar, carrageenan, pectin, gelatin, calcium alginate, carbomers, methyl cellulose, sodium carboxy methyl cellulose and other cellulose derivatives, carbopol, bentonite (preferably carbomers) may be used in combination with bioadhesives which includes, but not limited to, gelatin, carbopol 934, polycarbophil, cross-linked polymethacrylic acid, hydroxypropyl methyl cellulose, ethyl cellulose, preferably carbopol & methyl cellulose.
  • bioadhesives which includes, but not limited to, gelatin, carbopol 934, polycarbophil, cross-linked polymethacrylic acid, hydroxypropyl methyl cellulose, ethyl cellulose, preferably carbopol & methyl cellulose.
  • the chelating agents may be selected from, but not limited to disodium edetate, sodium citrate, condensed sodium phosphate, diethylenetriamine penta-acetic acid and like.
  • Film forming polymers may be selected from, but are not limited to carbomers such as carboxymethylene polymers including acrylic acid polymers, and acrylic acid copolymers, acrylic acid alkyl ester monomers, maleic acid alkyl esters, crotonic acid alkyl ester monomers, vinyl ester monomers, cellulose derivatives, vinylpyrrolidone- vinyl acetate copolymers, polyurethane, preferably carbopol, hydroxyethyl cellulose, methyl cellulose, vinylpyrrolidone-vinyl acetate copolymers.
  • carbomers such as carboxymethylene polymers including acrylic acid polymers, and acrylic acid copolymers, acrylic acid alkyl ester monomers, maleic acid alkyl esters, crotonic acid alkyl ester monomers, vinyl ester monomers, cellulose derivatives, vinylpyrrolidone- vinyl acetate copolymers, polyurethane, preferably carbopol, hydroxyethyl cellulose, methyl cellulose, vinyl
  • Antioxidants may be selected from but are not limited to ascorbate, BHT, BHA, sodium metabisulphite, alpha-tocopherol or its synthetic derivatives, EDTA and like.
  • Propellants may be selected from volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases or mixtures thereof, fluorohydrocarbon (HFCs) propellants such as 1,1,1,2-tetrafluorethane, and 1,1,1,2,3,3,3-heptafluoropropane, 1,1- difluoro ethane and 1,1,1,3,3,3-hexafluoropropane, preferably HFC 134a or HFA 227.
  • volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases or mixtures thereof
  • fluorohydrocarbon (HFCs) propellants such as 1,1,1,2-tetrafluorethane, and 1,1,1,2,3,3,3-heptafluoropropane
  • the topical pharmaceutical gel formulation comprise ciclopirox (or liposomal encapsulated ciclopirox) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and tenofovir (or liposomal encapsulated tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients such as gelling agents preferably carbopol and/or cellulose derivatives; lipid core preferably egg lecithin or soya lecithin; organic solvent preferably ethanol; preservatives and pH adjusting agents
  • the topical pharmaceutical formulation in the form of spray-foam comprise ciclopirox or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and tenofovir (or liposomal encapsulated tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients such as fatty alcohols preferably cetyl alcohol and stearyl alcohol; humectants preferably glycerin; surfactants preferably polyethylene glycol; emollients such as propylene glycol and propellant preferably hydrofluorocarbon [HFC- 134].
  • fatty alcohols preferably cetyl alcohol and stearyl alcohol
  • humectants preferably glycerin
  • surfactants preferably polyethylene
  • the topical pharmaceutical gel formulation comprises liposome en-capsulated tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients and one or more pharmaceutically acceptable excipients such as gelling agents preferably carbopol or cellulose derivatives; lipid core preferably egg lecithin or soya lecithin; organic solvent preferably ethanol; preservatives and pH adjusting agents
  • the topical pharmaceutical formulation in the form of spray-foam comprises liposome en-capsulated tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and Ciclopirox [or liposome en-capsulated ciclopirox] or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof one or more pharmaceutically acceptable excipients and one or more pharmaceutically acceptable excipients such as lipid core preferably egg lecithin or soya lecithin; film forming polymer preferably Kollidon VA64 and organic solvent such as ethanol.
  • lipid core preferably egg lecithin or soya lecithin
  • film forming polymer preferably Kollidon VA64 and organic solvent such as ethanol.
  • step (a) Dissolving an antiviral agent in a lipid core component with suitable organic solvent to obtain a solution; (b) Homogenizing the solution of step (a) solution with water;
  • a method of manufacturing the said topical pharmaceutical foam comprising: a. Dissolving a fatty alcohol and a surfactant in a suitable organic solvent to form a solution; b. Adding an antimycotic agent, an antiviral agent and an emollient/humectant to the solution c. Filling the aerosol foam in aluminium canisters and pressurizing with propellants
  • the fourth embodiment there is provided a method of manufacturing the said topical liposomal foam wherein the actives and lipid component were dissolved with other excipients in suitable organic solvent.
  • the composition according to the present invention may be formulated into pharmaceutical preparations common in the pharmaceutical field, which include, gel; a spray; a foam; a cream; a wash; a pessary; an ovule; a lotion; an ointment; a film; a foaming tablet; a tampon; a vaginal spray; solution; a bath; a liniment; a patch; a pad; a bandage
  • suitable excipients required for the formulation of the above mentioned dosage forms may be used.
  • the present composition may be mixed with oleaginous bases, which are exemplified by Vaseline, liquid paraffin, paraffin, plastibase, silicon, lard, vegetable oils, waxes and purified lanolin, water-soluble bases, emulsion bases, suspension bases, and the like.
  • oleaginous bases which are exemplified by Vaseline, liquid paraffin, paraffin, plastibase, silicon, lard, vegetable oils, waxes and purified lanolin, water-soluble bases, emulsion bases, suspension bases, and the like.
  • the ointments may be supplemented with an antioxidant (e.g, tocoperol, BHA, BHT, NDGA, etc.), an antiseptic (e.g., phenolic compounds, chlorobutanol, benzylalcohol, parabens, benzoic acid, etc.), a humectant (e.g., glycerin, propylene glycol, sorbitol, etc.), a solution adjuvant (e.g., ethanol, propylene glycol, etc.), a softening adjuvant (e.g., liquid paraffin, glycerin, propylene glycol, surfactants, etc.), and other additives.
  • an antioxidant e.g, tocoperol, BHA, BHT, NDGA, etc.
  • an antiseptic e.g., phenolic compounds, chlorobutanol, benzylalcohol, parabens, benzoic acid, etc.
  • the additives may be mixed with a propellant to disperse a water-dispersed concentrate or humidified powder.
  • a permeation stimulator may be used to increase the permeation of compounds through the skin.
  • the pH of the composition of the invention can be physiologically compatible and/or sufficient to maintain stability of the composition.
  • the composition of the present invention has a pH range of 4.0 to 6.0.
  • the present invention further provides for a method of prophylaxis and/or treatment of sexually transmitted infections including HIV/ AIDS and/or common vaginal infections by application and/or use of a therapeutically effective amount of the combination in a suitable pharmaceutical composition of the present invention to a mammal in need thereof.
  • a method of prophylaxis and/or treatment of sexually transmitted infections including HIV/ AIDS and/or common vaginal infections by application and/or use of a therapeutically effective amount of the combination in a suitable pharmaceutical composition of the present invention to a mammal in need thereof.
  • the antiviral agent is dissolved in lipid component with suitable organic solvent.
  • liposomal gel was formed by adding and stirring homogenized solution with slurry.
  • a diluent includes a single diluent as well as two or more different diluents
  • disintegrant refers to a single disintegrant or combination of two or more disintegrants, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.

Description

TOPICAL COMBINATIONS COMPRISING AN ANTIMYCOTIC AGENT AND AN ANTIVIRAL AGENT
Technical field:
The present invention relates to a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, in particular, for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.
Background and Prior art:
Sexually transmitted infections (STIs), referring to infections that are most often transmitted by direct sexual contact, remain an increasingly serious worldwide public health problem. These STIs, particularly viral infections, present a public health crisis.
Women are especially at risk as they are more susceptible to infection. Many STIs are asymptomatic and there is a high morbidity rate associated with untreated infections.
Since its recognition in 1981, the acquired immunodeficiency syndrome (AIDS) has become a catastrophic pandemic. The AIDS pandemic is a premiere public health concern. Individuals who are at high risk of HIV/ AID S infection are also at risk of infection by other sexually transmitted pathogens. Similarly, individuals at risk for non- HIV/AIDS sexually transmitted pathogens are also at high risk for HIV/ AIDS infection.
Additionally, it is significant to note that women comprise the most rapidly increasing population of the AIDS epidemic. Sexual transmission of HIV/ AIDS in women occurs by infected semen being placed into the vagina, rectum, or other orifice. Currently, the only prevention strategy available for HIV/ AID S prevention is by using condoms or abstaining from sexual intercourse.
Clinical pathologies attributable to STIs are profound. STIs cause acute and chronic infections, infertility, and in some cases, cancer. Vaccines, which are costly and time- consuming to develop, are not available for certain STIs such as HIV/AIDS prevention. HIV/AIDS treatment employs therapeutic strategies, such as retrovirus triple therapy (e.g., AZT, DDI, etc.) to lower virus burden. However, the high expense of treatment renders this therapeutic option practically unavailable to populations in developing countries where HIV/AIDS is most prevalent. Indeed, the sum of all available STI/ AID S therapeutics is effective against only a limited number of susceptible pathogens. Furthermore, this limited therapeutic arsenal is largely confined to proprietary formulations, which are costly for the afflicted to procure.
Common vaginal infections also pose an increasingly serious worldwide public health problem and can increase the risk of acquiring HIV/ AID S and other STIs. Vaginal candidiasis is the most common form of vaginitis, occurring more frequently than trichophyton, chlamydia, gonorrhea, or other bacterial infections. It is estimated that 75% of women will experience at least one episode of vulvovaginal candidiasis in their lifetime. 40 to 50% will experience a second episode in their life-time. A much smaller (probably less than 5%), but still significant, number of women will suffer from repeated, often intractable attacks. Candidiasis is known to increase the risk of HIV/AIDS acquisition. Bacterial vaginosis (BV), previously known as nonspecific vaginitis or Gardnerella vaginitis is the most common cause of vaginal discharge. It may be the cause of up to 50% of cases of vaginitis in all women and from 10-30% in pregnant women. BV is not a sexually transmitted disease although it is sometimes listed as one. However, the risk of contracting the disease increases with multiple sex partners. Although treatment is available for these diseases, methods to prevent them and improved methods of treatment are still needed.
Presently marketed vaginal contraceptive compositions, often containing nonoxynol-9 as an active ingredient, are generally known in the art. While presently marketed vaginal contraceptive formulations aid in preventing pregnancy, their ability to effectively prevent STIs, particularly HIV/ AIDS as well as oral, rectal and vaginal infections, is very limited. Nonoxynol-9 and other detergents as well as their compositions can destroy the natural and safe ecology of the vagina, such as by inactivating lactobacillus bacteria. Further, spermicides may cause vaginal irritation, particularly with frequent exposure or higher doses. Recent analyses show that nonoxynol-9, when used frequently by women at high risk, may increase the risk of HIV infection (WHO 2002, WHO/CONRAD technical consultation on nonoxynol-9, Geneva).
Many antiviral agents have been developed for the treatment of patients with human immunodeficiency virus (HIV) infection. However, only temporary and limited benefits are observed in HIV-infected patients treated with any of the actual anti-retrovirals or combinations of them. The limited ability of these agents to decrease viral burden, the rapid development of resistance and the toxic side-effects of most drugs has limited their long-term efficacy. One major problem associated with the administration of antiviral agents to patients is their poor ability to penetrate and target infected cells. Rapid drug clearance and the toxicity of parent compounds or metabolites constitute also some of the major drawbacks which may slow down the development and use of many antiviral agents. Given the severe toxicity of antiviral agents actually available to treat AIDS and other viral diseases and their limited ability to target infected cells, strategies aimed at reaching therapeutic levels of drags into infected cells and reducing toxicity should be explored.
US20050037033 discloses a microbicidal compositions containing Ciclopirox olamine for preventing the transmission of or treating sexually transmitted infections and/or common vaginal infections.
WO9602226 discloses a pharmaceutical composition comprising a combination of 1- hydroxy-2-pyridones such as Ciclopirox or Octopirox and Crotamiton as an antifungal agent activity enhancer.
WO9717075 discloses a topical foamable pharmaceutical composition of Ciclopirox or Ciclopirox olamine and surfactant for treating skin diseases induced by oval Pityrosporum. US20050196418 discloses a composition comprising a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof.
US20050276836 discloses a vaginal device for delivering therapeutic and/or health- promoting agents, wherein said vaginal device is a vaginal tampon, vaginal tampon-like device, vaginal ring & others.
US patents 4,108,309; 4,360,013; and 4,589,880 disclose suitable devices for applying the composition to the vagina.
US 5,292,516 disclose process of treating a condition by means of application of in-situ gel formulations comprising poloxamers administered by means of medical device.
However use of such delivery devices for applying compositions to the vagina may cause an internal harm for ex: rashes or bleeding.
There still remains a need to develop a medicament and/or formulation which stand against a multitude of resistant strains, could protect the drug against enzymatic degradation, improve their pharmacokinetics & tissue distribution, while minimizing disruptions to vaginal ecology and epithelium.
Object of the invention:
The object of the present invention is to provide a novel pharmaceutical composition, in particular, for prophylaxis and/or treatment of sexually transmitted infections including HIV/ AIDS and/or common vaginal infections which stands against resistant strains.
Another object of the present invention is to provide a novel composition, in particular, for prophylaxis and/or treatment of sexually transmitted infections including HIV/AIDS and/or common vaginal infections while rninimizing disruptions to vaginal ecology and epithelium without compromising the stability and efficacy of the formulation. Yet another object of the present invention is to provide topical liposomal formulations of drugs for the treatment of sexually transmitted infections including HTV/ AIDS and/or related vaginal infections that result in an increased efficacy and reduced toxicity of antiviral agents in humans suffering from sexually transmitted infections including HTV and/or related vaginal infections.
Still another object of the present invention is to provide a novel pharmaceutical composition and/or medicament with ease of manufacture.
Summary of the invention:
According to one aspect, there is provided a novel pharmaceutical composition for topical administration comprising one or more antimycotics or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more anti-viral agent/s or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
According to a second aspect, there is provided a novel pharmaceutical composition for topical administration comprising Ciclopirox or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and Tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients. According to a third aspect, there is provided a novel pharmaceutical composition for topical administration comprising liposome en-capsulated Tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof wherein the said liposomes allows high cellular penetration, good in vitro antiviral activity against HIV which in turn provides a marked improvement of the pharmacokinetics of drugs.
According to a fourth aspect, there is provided a process of manufacturing the said novel pharmaceutical composition for topical administration comprising Ciclopirox or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof; one or more anti-viral agent/s or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
According to a fifth aspect, there is provided a process of manufacturing the said novel pharmaceutical composition for topical administration comprising liposome encapsulated tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
According to a further aspect, there is provided a novel pharmaceutical composition for topical administration for prophylaxis and/or treatment of sexually transmitted infections including HIV/ AID S and/or related vaginal infections. Any of the active materials described and claimed in this specification may be provided in the form of the free material or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
Detailed Description:
The inventors have surprisingly found that by incorporation of liposome en-capsulated Tenofovir in a suitable topical formulation (e.g. gel composition or spray foam) prevented the transmission of infectious pathogens and its permeation through the membrane of mucosa by means of physical cum pharmacological barrier thereby preventing infection of host cells.
It was further found that by topical application of combination of anti-infectives like Ciclopirox and/or Tenofovir resulted better penetration in the fungal and vaginal infections, thereby destroying plasma membrane which in turn prevented or limited contact of the fungus and/or virus or its carrier cells with the epithelium or prevented or hindered its entry into the orifice by forming a physical cum pharmacological barrier and thus preventing recurrence of infection for a considerable period of time.
Liposomes are microscopic vesicles in which a variety of drugs can be incorporated, to form a non-toxic and biodegradable formulation because of the similarity of the primary components of liposomes with natural membranes. It allows high cellular penetration, efficient targeting of macrophage-rich tissues and a marked improvement in drug pharmacokinetics.
The liposomal topical formulation, according to the present invention, provides improved delivery of active agents to the infected cells and also reduces the toxic effects associated with their administration which in turn improved efficacy and safety of the drug used for the treatment of sexually transmitted infections including HIV/AIDS and/or related vaginal infections.
When applied locally to mucosa or skin, liposomes are usually taken up by monocytes and macrophages and also by Langerhans cells which may capture and harbor HIV. Consequently, in contrast with free drugs, which tend to diffuse rapidly through the mucosa and reach the circulation, the use of drugs within liposomes and incorporated into a topical formulation (e.g. gel formulation or spray foam) concentrates the active agents within infected cells as well as within cells susceptible to HIV infection.
It will be well acknowledged to a person skilled in the art that combination of anti- mycotic (e.g. Ciclopirox) with liposome encapsulated Tenofovir when applied topically; may achieve the same benefits as described above.
According to preferred embodiment, topical combination comprising ciclopirox and tenofovir (or liposome encapsulated tenofovir) exhibited excellent anti-infective activity against opportunistic infections encountered in STFs and/or AIDS, such as vaginal infections without compromising on the stability of the formulation.
According to the present invention, the protection from sexually transmitted infections, such as HIV/AIDS, and common vaginal infections, such as bacterial vaginosis and vaginal candidiasis, may be obtained by application of the novel pharmaceutical composition to vagina, rectum or other orifice.
According to the present invention, pharmaceutical compositions may be used alone or in conjunction with delivery and/or contraceptive devices or methods, such as mechanical barrier-type devices. Pharmaceutical compositions, according to the present invention, may be formulated in various dosage forms including a base or carrier, such as a foam, cream, wash, gel, suppository, ovule, lotion, ointment, film, foaming tablet, tampon, vaginal spray, or aerosol. According to the present invention, the novel pharmaceutical composition for topical administration may encompass one or more anti-infectives selected from the class of, but not limited to, antimycotics, antimycobacterials, antibacterials, antivirals or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
Accordingly, as a preferred embodiment, a novel pharmaceutical composition for topical administration may comprise antimycotics (e.g. Ciclopirox) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and Tenofovir (or liposome encapsulated Tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients for prophylaxis and/or treatment of STI 's including HTV/ AID S and related viral infections .
Alternatively, the novel pharmaceutical composition for topical administration may comprise one or more antimycotics selected from the class of, but not limited to ketoconazole, itraconazole, fluconazole, ravuconazole, posaconazole, voricnazole, caspofungin, hydroxypyridones derivatives such as ciclopirox, mimosine, deferipone or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof with one or more antiviral agents selected from the class of, but not limited to Tenofovir, Acyclovir and Ganciclovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
As a preferable embodiment, the pharmaceutical composition for topical administration may comprise liposome encapsulated tenofovir with one or more pharmaceutically acceptable excipients or combination of ciclopirox [or liposome encapsulated ciclopirox] or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof with tenofovir (or liposome encapsulated tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients.
According to the present invention, the pharmaceutical formulations may be applied to the body cavities such as the vagina and rectum. It will be readily acknowledged to a person skilled in the art; that the formulation may also be applied to the skin and other mucous membranes. Preferably, the said novel pharmaceutical formulations inactivate bacteria, fungi and/or viruses, and are stable at ambient temperature, compatible and active after mixture with cosmetically acceptable formulations, non-toxic and non- damaging to vulvar, vaginal, cervical, penile or other epithelium.
The pharmaceutical composition of the present invention prevents the transmission of or treats sexually transmitted infections and/or common vaginal infections. Sexually transmitted infections include, but are not limited to, HIV/AIDS, herpes (caused by herpes simplex virus type 1 (HSV-I) or herpes simplex virus type 2 (HSV-2)), gonorrhea, Chlamydia, syphilis, and trichomoniasis. Common vaginal infections include, but are not limited to, bacterial vaginosis (BV) and vaginal candidiasis. Similar compositions and methods of application of such compositions, as described herein, can be used for treating sexually transmitted infections and/or common vaginal infections and for preventing the transmission of sexually transmitted infections and/or common vaginal infections.
Preferably, the present invention involves the topical application of the formulation. In the context of the present invention, it is to be understood that the term topical application includes application to the body cavities as well as to the skin. Thus, in a preferred embodiment, the formulation is applied to a body cavity such as the vagina, anus, rectum or mouth. In a particularly preferred embodiment, the composition is applied to the vagina.
In a preferred embodiment, the topical application is carried out prior to the beginning of vaginal intercourse, preferably from 0 to 8 hours, more preferably from 0 to 60 minutes. The composition including the combination may be used independent from intercourse.
According to the preferred embodiments, the pharmaceutically acceptable excipients may include, but are not limited to, one or more surfactant, emollient or humectant, pH adjusting agent, fatty alcohol, preservative, lipid core components (e.g. phospholipids), organic solvent, gelling agents, chelating agents, film forming polymers, antioxidants, propellants or combinations thereof based on the type/route of administration of the formulation.
The surfactants may be selected from, but not limited to, Polyoxyethylene alcohol, alkylphenol ethoxylate, polysorbate 80, polysorbate 60, polymethylsiloxane, alkylphenol ethoxylate, poloxomer 407, sorbitan nionostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, polyethylene glycol (PEG) stearic acid esters (e.g. polyethylene glycol 100 stearate).
Suitable humectants and/or emollients provide smoothness and lubricity which, in turn, facilitate the loading and dispensing of the formulation. The emollients and/or humectants may be selected from, but not limited to, polyhydric alcohols such as glycols, and polysaccharides, such as ethylene glycol, propylene glycol, butylene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, sorbitol, malvitol, trehalose, raffinose, xylitol, mannitol, polyethylene glycol, propylene glycol, polyglycerin, cholesterol, squaline, fatty acids, octyldodecanol, myristyl alcohol, urea, lanolin, lactic acid, esters such as isopropyl stearate, isopropyl myristate, isopropyl palmitate and isopropyl laurate and the like.
The pH adjusting agents may be selected from, but not limited to, lactic acid, sodium hydroxide, acetic acid, citric acid, tartaric acid, propionic acid, sodium phosphate, ammonia solution, triethanolamine, sodium borate, sodium carbonate, potassium hydroxide and like.
The fatty alcohols may be selected from, but not limited to, stearyl alcohol, cetyl alcohol, capryl alcohol, myristyl alcohol, 1-dodecanol, palitoleyl alcohol, oleyl alcohol, linoleyl alcohol, isostearyl alcohol and like, preferably stearyl alcohol and cetyl alcohol.
The preservatives may be selected from, but not limited to, benzyl alcohol, hydroxybenzoates (parabens), Benzoic Acid, Chlorphenesin, Sorbic Acid, Phenoxyethanol and like.
Lipid core components may be selected from, but not limited to, natural phospholipids such as egg yolk lecithin (phosphatidylcholine), soybean lecithin, lysolecithin, sphingomyelin, phosphatide acid, phosphatidylserine, phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, cardiolipin, plasmalogen, etc., or hydrogenation products obtainable from said phospholipids by the conventional technology (Hydrogenated soy phosphatidyl choline), and synthetic phospholipids such as dicetyl phosphate, distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidyl glycerol, distearoylphosphatidyl glycerol, dilaurylphosphatidylglycerol, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine, eleostearoylphosphatidylserine, dipalmitoylphosphatidyl acid, dipalmitoylphosphatidyl ethanolamine, their salts and the corresponding distearoyl- and dimyristyl- counterparts and/or mixtures thereof.
These lipids or their mixtures may further contain substances selected from dicetylphosphate, cholesterol, coprostanol, cholestanol, cholestane, ergosterol, phytosterol, sitosterol, lanosterol, protein (e.g. albumin, immunoglobulin, casein, insulin, hemoglobin, lysozyme, immunoglobulin, [alpha]-2-macroglobulin, fibronectin, vitronectin, fibrinogen, lipase, or enzyme) which strengthens the lipid and other additives like α-tocopherol, stearic acid, antioxidants, BHT (butylhydroxytoluene), ascorbic acid, deferoxime mesylate, stearyl amine and/or mixtures thereof.
Alternatively, gelling agents such as, alginic acid, sodium alginate, potassium alginate, agar, carrageenan, pectin, gelatin, calcium alginate, carbomers, methyl cellulose, sodium carboxy methyl cellulose and other cellulose derivatives, carbopol, bentonite (preferably carbomers) may be used in combination with bioadhesives which includes, but not limited to, gelatin, carbopol 934, polycarbophil, cross-linked polymethacrylic acid, hydroxypropyl methyl cellulose, ethyl cellulose, preferably carbopol & methyl cellulose.
The chelating agents may be selected from, but not limited to disodium edetate, sodium citrate, condensed sodium phosphate, diethylenetriamine penta-acetic acid and like.
Film forming polymers may be selected from, but are not limited to carbomers such as carboxymethylene polymers including acrylic acid polymers, and acrylic acid copolymers, acrylic acid alkyl ester monomers, maleic acid alkyl esters, crotonic acid alkyl ester monomers, vinyl ester monomers, cellulose derivatives, vinylpyrrolidone- vinyl acetate copolymers, polyurethane, preferably carbopol, hydroxyethyl cellulose, methyl cellulose, vinylpyrrolidone-vinyl acetate copolymers.
Antioxidants may be selected from but are not limited to ascorbate, BHT, BHA, sodium metabisulphite, alpha-tocopherol or its synthetic derivatives, EDTA and like. Propellants may be selected from volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases or mixtures thereof, fluorohydrocarbon (HFCs) propellants such as 1,1,1,2-tetrafluorethane, and 1,1,1,2,3,3,3-heptafluoropropane, 1,1- difluoro ethane and 1,1,1,3,3,3-hexafluoropropane, preferably HFC 134a or HFA 227.
According to a first preferred embodiment of the present invention, the topical pharmaceutical gel formulation comprise ciclopirox (or liposomal encapsulated ciclopirox) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and tenofovir (or liposomal encapsulated tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients such as gelling agents preferably carbopol and/or cellulose derivatives; lipid core preferably egg lecithin or soya lecithin; organic solvent preferably ethanol; preservatives and pH adjusting agents
According to a second preferred embodiment of the present invention, the topical pharmaceutical formulation in the form of spray-foam comprise ciclopirox or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and tenofovir (or liposomal encapsulated tenofovir) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients such as fatty alcohols preferably cetyl alcohol and stearyl alcohol; humectants preferably glycerin; surfactants preferably polyethylene glycol; emollients such as propylene glycol and propellant preferably hydrofluorocarbon [HFC- 134]. According to a third preferred embodiment of the present invention, the topical pharmaceutical gel formulation comprises liposome en-capsulated tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and one or more pharmaceutically acceptable excipients and one or more pharmaceutically acceptable excipients such as gelling agents preferably carbopol or cellulose derivatives; lipid core preferably egg lecithin or soya lecithin; organic solvent preferably ethanol; preservatives and pH adjusting agents
According to a fourth preferred embodiment of the present invention, the topical pharmaceutical formulation in the form of spray-foam comprises liposome en-capsulated tenofovir or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof and Ciclopirox [or liposome en-capsulated ciclopirox] or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof one or more pharmaceutically acceptable excipients and one or more pharmaceutically acceptable excipients such as lipid core preferably egg lecithin or soya lecithin; film forming polymer preferably Kollidon VA64 and organic solvent such as ethanol.
According to the present invention, there is further provided process/method(s) of preparing the said pharmaceutical composition.
According to the above mentioned embodiment, there is provided a method of manufacturing the said topical pharmaceutical liposomal gel comprising:
(a) Dissolving an antiviral agent in a lipid core component with suitable organic solvent to obtain a solution; (b) Homogenizing the solution of step (a) solution with water;
(c) Introducing an antimycotic agent, a film forming polymer and a preservative in water, followed by pH adjustment, to form a slurry; and
(d) Forming a liposomal gel by adding and stirring the homogenized solution with the slurry.
According to the second embodiment, there is provided a method of manufacturing the said topical pharmaceutical foam comprising: a. Dissolving a fatty alcohol and a surfactant in a suitable organic solvent to form a solution; b. Adding an antimycotic agent, an antiviral agent and an emollient/humectant to the solution c. Filling the aerosol foam in aluminium canisters and pressurizing with propellants
According to the third embodiment, there is provided a method of manufacturing the said topical liposomal spray comprising:
(a) Dissolving the actives in lipid component along with soya lecithin and Kollidon V A 64 in a suitable organic solvent.
(b) Filling the above solution in aluminium canisters and pressurizing with propellant.
According to the fourth embodiment, there is provided a method of manufacturing the said topical liposomal foam wherein the actives and lipid component were dissolved with other excipients in suitable organic solvent.
According to the intended therapeutic purpose, the composition according to the present invention may be formulated into pharmaceutical preparations common in the pharmaceutical field, which include, gel; a spray; a foam; a cream; a wash; a pessary; an ovule; a lotion; an ointment; a film; a foaming tablet; a tampon; a vaginal spray; solution; a bath; a liniment; a patch; a pad; a bandage According to present invention suitable excipients required for the formulation of the above mentioned dosage forms may be used.
Alternatively, for ointment formulation, taking into consideration various factors including temperature of the skin surface, pH of the skin, transdermal water loss levels and total lipid levels of the epidermis, the present composition may be mixed with oleaginous bases, which are exemplified by Vaseline, liquid paraffin, paraffin, plastibase, silicon, lard, vegetable oils, waxes and purified lanolin, water-soluble bases, emulsion bases, suspension bases, and the like. The ointments may be supplemented with an antioxidant (e.g, tocoperol, BHA, BHT, NDGA, etc.), an antiseptic (e.g., phenolic compounds, chlorobutanol, benzylalcohol, parabens, benzoic acid, etc.), a humectant (e.g., glycerin, propylene glycol, sorbitol, etc.), a solution adjuvant (e.g., ethanol, propylene glycol, etc.), a softening adjuvant (e.g., liquid paraffin, glycerin, propylene glycol, surfactants, etc.), and other additives.
Alternatively, for spray formulation, the additives may be mixed with a propellant to disperse a water-dispersed concentrate or humidified powder. For patch formulation, a permeation stimulator may be used to increase the permeation of compounds through the skin.
The pH of the composition of the invention can be physiologically compatible and/or sufficient to maintain stability of the composition. According to preferred embodiments, the composition of the present invention has a pH range of 4.0 to 6.0.
The present invention further provides for a method of prophylaxis and/or treatment of sexually transmitted infections including HIV/ AIDS and/or common vaginal infections by application and/or use of a therapeutically effective amount of the combination in a suitable pharmaceutical composition of the present invention to a mammal in need thereof. The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the present invention.
Ciclopirox and Tenofovir vaginal liposomal gel: Formula:
Figure imgf000019_0001
Process:
(a) The antiviral agent was dissolved in lipid component with suitable organic solvent and homogenized;
(b) The antimycotic agent was dissolved in lipid component with suitable organic solvent and homogenized;
(b) Slurry of firm forming polymers and preservatives was made in water followed by pH adjustment.
(c) Finally, liposomal gel was formed by adding and stirring homogenized solutions of steps [a] and [b] with slurry. Ciclopirox and Tenofovir vaginal liposomal gel: Formula:
Figure imgf000020_0001
Process:
(c) The antiviral agent is dissolved in lipid component with suitable organic solvent.
(d) The above solution was then homogenized in water.
(e) Slurry of antimycotic agent, film forming polymers and preservatives was made in water followed bypH adjustment.
(f) Finally, liposomal gel was formed by adding and stirring homogenized solution with slurry.
Ciclopirox and Tenofovir vaginal foam:
Figure imgf000020_0002
Figure imgf000021_0001
Process:
(1) Cetyl alcohol, stearyl alcohol and Polyethylene glycol- 100 stearate was dissolved in ethanol.
(2) To the above solution, Ciclopirox and Tenofovir were added.
(3) Propylene glycol and Glycerin were then added to the solution obtained in step (2) and mixed.
(4) Finally, the above solution was filled in aluminium canisters and pressurized with propellant.
Tenofovir liposomal gel:
Figure imgf000021_0002
Procedure: (1) Tenofovir disoproxil fumarate and Lecithin were dissolved in Ethanol.
(2) The above solution was the added in water under ultraturrax and Homogenized for 20 rain.
(3) Slurry of Carbopol or Methyl cellulose in water was made containing dissolved methyl and propyl paraben.
(4) pH was adjusted with Triethanol amine, if required.
(5) The homogenize blend was added in Carbopol or Methyl cellulose slurry. Finally it was stirred for 30 min to form a liposomal gel.
Tenofovir liposomal spray:
Figure imgf000022_0001
Procedure:
(1) Tenofovir disoproxil fumarate, N- vinylpyrrolidone- vinyl acetate copolymer were dissolved in ethanol.
(2) Ciclopirox olamine, N-vinylpyπOlidone-vinyl acetate copolymer were dissolved in ethanol.
(3) The above solutions were combined and filled in aluminium canisters and pressurized with propellant.
Tenofovir liposomal spray:
Figure imgf000022_0002
Figure imgf000023_0001
Procedure:
(1) Tenofovir disoproxil fumarate, N-vinylpyrrolidone-vinyl acetate copolymer were dissolved in ethanol and then ciclopirox olamine was added.
(3) The above solution was filled in aluminium canisters and pressurized with propellant.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the spirit of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by the preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and such modifications and variations are considered to be falling within the scope of the invention.
It is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having" and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a diluent" includes a single diluent as well as two or more different diluents, reference to a "disintegrant" refers to a single disintegrant or combination of two or more disintegrants, and the like.

Claims

Claims
1. A pharmaceutical composition comprising an antimycotic agent and an antiviral agent, optionally in combination with one or more pharmaceutically acceptable excipients.
2. A pharmaceutical composition according to claim 1 wherein the antimycotic agent is ketoconazole; itraconazole; fluconazole; ravuconazole; posaconazole; voricnazole; caspofungin; or a hydroxypyridone derivative, such as ciclopirox, mimosine, or deferipone and the antiviral agent is Tenofovir, Acyclovir and/or Ganciclovir.
3. A pharmaceutical composition according to any preceding claim wherein the preferred antimycotic agent is Ciclopirox and the preferred antiviral agent is Tenofovir.
4. A pharmaceutical composition according to any preceding claim, which is in the form of a gel; a spray; a foam; a cream; a wash; a pessary; an ovule; a lotion; an ointment; a film; a foaming tablet; a tampon; a vaginal spray; solution; a bath; a liniment; a patch; a pad; a bandage.
5. A pharmaceutical composition according to claim 4 wherein the composition is in the form of a gel or spray.
6. A pharmaceutical composition according to claim 5 comprising liposomes and wherein the antiviral agent and/or the antimycotic agent is encapsulated in the liposomes.
7. A pharmaceutical composition according to claim 6, wherein the liposomes comprise: a natural phospholipid such as egg yolk lecithin (phosphatidylcholine), soybean lecithin, lysolecithin, sphingomyelin, phosphatide acid, phosphatidylserine, phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, cardiolipin, plasmalogen; a hydrogenation product obtainable from a natural phospholipid, such as hydrogenated soy phosphatidyl choline; a synthetic phospholipid such as dicetyl phosphate, distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidyl glycerol, distearoylphosphatidyl glycerol, dilaurylphosphatidylglycerol, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine, eleostearoylphosphatidylserine, dipalmitoylphosphatidyl acid, dipalmitoylphosphatidyl ethanolamine; their salts and/or the corresponding distearoyl- and diniyristyl- counterparts; and any combination thereof.
8. A pharmaceutical composition according to claim 6 wherein the liposomes further comprise: dicetylphosphate; cholesterol; coprostanol; cholestanol; cholestane; ergosterol; phytosterol; sitosterol; lanosterol; protein, such as albumin, immunoglobulin, casein, insulin, hemoglobin, lysozyme, immunoglobulin, [alpha]-2- macroglobulin, fibronectin, vitronectin, fibrinogen, lipase, or enzyme; α-tocopherol; stearic acid; BHT (butylhydroxytoluene); ascorbic acid; deferoxime mesylate; stearyl amine; and any combination thereof.
9. A pharmaceutical composition according to claims 5 and 8 comprising a polymer matrix, wherein the antimycotic agent is dispersed in the polymer matrix
10. A pharmaceutical composition according to any preceeding claims wherein the polymer matrix comprises a gelling agent.
11. A pharmaceutical composition according to any preceeding claims wherein the polymer matrix comprises a film forming polymer.
12. A pharmaceutical composition according to any preceding claim having a pH in the range of from 4.0 to 6.0.
13. A pharmaceutical composition according any preceding claim, which is in the form of a gel formulation comprising liposomes and a polymeric matrix, wherein tenofovir is encapsulated in the liposomes and ciclopirox is dispersed in the polymer matrix.
14. A pharmaceutical composition according any preceding claim, which is in the form of a spray formulation comprising liposomes and a polymeric matrix, wherein tenofovir is encapsulated in the liposomes and ciclopirox is dispersed in the polymer matrix.
15. A pharmaceutical composition according to claim 9, 14 and 15, wherein the tenofovir and/or ciclopirox are encapsulated in the liposomes.
16. A pharmaceutical composition according to claim 4 optionally further comprising a propellant selected from: a volatile hydrocarbon such as butane, propane, isobutene; or a fluorohydrocarbon (HFCs) propellant such as 1,1,1,2-tetrafluorethane, and 1,1,1,2,3,3,3-heptafluoropropane, 1,1-difluoro ethane and 1,1,1,3,3,3- hexafluoropropane, and HFC 134a; of any combination thereof.
17. A method of manufacturing a topical pharmaceutical gel composition, comprising the steps of:
(a) Dissolving an antiviral agent hi a lipid core component with suitable organic solvent to obtain a solution;
(b) Homogenizing the solution of step (a) solution with water;
(c) Introducing an antimycotic agent, a film forming polymer and a preservative hi water, followed by pH adjustment, to form a slurry; and
(d) Forming a gel by adding and stirring the homogenized solution with the slurry.
18. A method of manufacturing a topical pharmaceutical gel composition, comprising the steps of:
(a) Dissolving an antiviral agent in a lipid core component with suitable organic solvent to obtain a solution; and further homogenizing the solution with water (b) Dissolving an antimycotic agent in a lipid core component with suitable organic solvent to obtain a solution; and further homogenizing the solution with water.
(c) Introducing a film forming polymer and a preservative in water, followed by pH adjustment, to form a slurry; and
(d) Forming a gel by adding and stirring the homogenized solutions of steps [a] and [b] with the slurry
19. A method of manufacturing a topical pharmaceutical foam composition, comprising the steps of:
(a) Dissolving a fatty alcohol and a surfactant in a suitable organic solvent to form a solution;
(b) Adding an antimycotic agent, an antiviral agent and an emollient/humectant to the solution;
(c) Filling a canister with the solution, and pressurizing the canister with a propellant.
20. A method of manufacturing a topical pharmaceutical spray composition, comprising the steps of:
(a) Dissolving antiviral agent, soya lecithin and copolymer of N-vinylpyrrolidone- vinyl acetate in ethanol and then adding ciclopirox to it.
(b) Filling the above solution in aluminium canisters and pressurizing with propellant.
21. A method of manufacturing a topical pharmaceutical spray composition, comprising the steps of:
(a) Dissolving antiviral agent, soya lecithin and copolymer of N-vinylpyrrolidone- vinyl acetate in ethanol.
(b) Dissolving mycotic agent, soya lecithin and copolymer of N-vinylpyrrolidone- vinyl acetate in ethanol.
(c) Combining and filling the above solutions of step [a] and [b] in aluminium canisters and pressurizing with propellant.
PCT/GB2009/000975 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent WO2009127825A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0907317A BRPI0907317A2 (en) 2008-04-16 2009-04-16 pharmaceutical composition and method for making a gel, foam and spray topical pharmaceutical composition
AU2009237478A AU2009237478A1 (en) 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent
EP09732346A EP2282777A1 (en) 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent
CN200980113498XA CN102006889A (en) 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent
JP2011504526A JP2011518140A (en) 2008-04-16 2009-04-16 Topical combination including antifungal and antiviral drugs
CA2721457A CA2721457A1 (en) 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent
US12/988,155 US20110104262A1 (en) 2008-04-16 2009-04-16 Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent
MX2010011244A MX2010011244A (en) 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent.
ZA2010/07309A ZA201007309B (en) 2008-04-16 2010-10-13 Topical combinations comprising an antimycotic and an antiviral agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN862/MUM/2008 2008-04-16
IN862MU2008 2008-04-16

Publications (1)

Publication Number Publication Date
WO2009127825A1 true WO2009127825A1 (en) 2009-10-22

Family

ID=40901978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/000975 WO2009127825A1 (en) 2008-04-16 2009-04-16 Topical combinations comprising an antimycotic agent and an antiviral agent

Country Status (12)

Country Link
US (1) US20110104262A1 (en)
EP (1) EP2282777A1 (en)
JP (1) JP2011518140A (en)
KR (1) KR20110003534A (en)
CN (1) CN102006889A (en)
AU (1) AU2009237478A1 (en)
BR (1) BRPI0907317A2 (en)
CA (1) CA2721457A1 (en)
MX (1) MX2010011244A (en)
RU (1) RU2010146482A (en)
WO (1) WO2009127825A1 (en)
ZA (1) ZA201007309B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084610A1 (en) * 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes for preventing the spread of hiv
EP2391344A1 (en) * 2009-01-30 2011-12-07 Yissum Research Development Company of the Hebrew University of Jerusalem Compositions for nail and skin treatment
WO2011156416A1 (en) * 2010-06-11 2011-12-15 Gilead Sciences, Inc. Topical antiviral formulations for prevention of transmission of hsv-2
CN102525883A (en) * 2010-12-09 2012-07-04 丽珠集团丽珠制药厂 Voriconazole suppository and preparation method and application thereof
WO2014041378A3 (en) * 2012-09-14 2014-05-30 Cipla Limited Topical pharmaceutical composition comprising tenofovir, an antibacterial agent and,optonally ciclopirox
US10022373B2 (en) 2014-04-11 2018-07-17 Sinotherapeutics Inc. Posaconazole pharmaceutical compositions and preparation methods, uses and pharmaceutical formulations thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102505180A (en) * 2011-09-16 2012-06-20 彭可扬 Itraconazole-lysozyme loaded electro-spun fibrous membrane for preventing and controlling indoor microbial pollution
KR101154328B1 (en) * 2011-10-27 2012-06-14 주식회사 에코산업 manufacturing method of hydrogel patch for treating the athlete's foot
SG11201408243VA (en) * 2012-06-13 2015-01-29 Evofem Inc Compositions and methods for enhancing the efficacy of contraceptive microbicides
KR101388855B1 (en) * 2013-02-08 2014-04-24 경북대학교 산학협력단 Composition of antibiotics containing imidazole or pyridine appended cholestane derivatives or pharmaceutically acceptable salts thereof
AU2014368971B2 (en) 2013-12-19 2020-02-06 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
WO2017161136A1 (en) * 2016-03-18 2017-09-21 Oak Crest Institute Of Science Acid salts for vaginal drug delivery
CN110225750A (en) 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 The treatment and prevention method of bacterial vaginosis BV
CN108619495A (en) * 2018-04-24 2018-10-09 金寨县鑫和新能源科技有限公司 A kind of composition of the health products of auxiliary treatment pelvic hydrops
CN112891323B (en) * 2020-01-22 2023-08-18 首都医科大学附属北京地坛医院 anti-HIV external disinfectant and preparation method thereof
IT202000017125A1 (en) * 2020-07-15 2022-01-15 Univ Degli Studi Padova COMPOUND AND PHARMACEUTICAL COMPOSITION FOR USE IN THE METHOD OF TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTIONS
CN115400086B (en) * 2022-10-08 2023-08-22 山东新时代药业有限公司 Policresulen liposome, preparation and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045795A2 (en) * 1999-02-05 2000-08-10 Cipla Limited Topical sprays comprising a film forming composition
WO2003082193A2 (en) * 2002-03-26 2003-10-09 Eastern Virginia Medical School Suramin and derivatives thereof as topical microbicide and contraceptive
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108309A (en) * 1976-10-15 1978-08-22 All One God Faith, Inc. Contraceptive containing device
US4360013A (en) * 1980-04-21 1982-11-23 Minnesota Mining And Manufacturing Company Polymeric acid contraceptive devices
US4589880A (en) * 1983-07-14 1986-05-20 Southern Research Institute Disposable spermicide-releasing diaphragm
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
WO1995012602A1 (en) * 1993-11-05 1995-05-11 Meiji Milk Products Co., Ltd. Antibacterial, antifungal and antiviral agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
WO2000045795A2 (en) * 1999-02-05 2000-08-10 Cipla Limited Topical sprays comprising a film forming composition
WO2003082193A2 (en) * 2002-03-26 2003-10-09 Eastern Virginia Medical School Suramin and derivatives thereof as topical microbicide and contraceptive
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATCHELOR J ET AL: "Skin disorders affecting the vulva", OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE 200803 GB, vol. 18, no. 3, March 2008 (2008-03-01), pages 53 - 59, XP002540230, ISSN: 1751-7214 *
RASKOVIC D ET AL: "Liposomes: A promising future for dermatocosmetology and clinical dermatology", JOURNAL OF LIPOSOME RESEARCH 1993 US, vol. 3, no. 3, 1993, pages 737 - 751, XP009120966, ISSN: 0898-2104 *
SZYMCZAK A: "Maintenance therapy of opportunistic infectious - Recommendations of polish scientific", HIV AND AIDS REVIEW 200612 PL, vol. 5, no. 4, December 2006 (2006-12-01), pages 18 - 19, XP001539623, ISSN: 1730-1270 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2391344A1 (en) * 2009-01-30 2011-12-07 Yissum Research Development Company of the Hebrew University of Jerusalem Compositions for nail and skin treatment
EP2391344A4 (en) * 2009-01-30 2012-08-08 Yissum Res Dev Co Compositions for nail and skin treatment
US9668987B2 (en) 2009-01-30 2017-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for nail and skin treatment
WO2011084610A1 (en) * 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes for preventing the spread of hiv
WO2011156416A1 (en) * 2010-06-11 2011-12-15 Gilead Sciences, Inc. Topical antiviral formulations for prevention of transmission of hsv-2
CN103079561A (en) * 2010-06-11 2013-05-01 吉里德科学公司 Topical antiviral agents for the prevention of HSV-2 transmission
JP2013528219A (en) * 2010-06-11 2013-07-08 ギリアード サイエンシーズ， インコーポレイテッド Topical antiviral formulation to prevent transmission of HSV-2
AU2011264952B2 (en) * 2010-06-11 2014-08-14 Quarraisha Abdool Karim Topical antiviral formulations for prevention of transmission of HSV-2
CN103079561B (en) * 2010-06-11 2015-12-02 吉里德科学公司 Topical antiviral formulations for prevention of HSV-2 transmission
CN102525883A (en) * 2010-12-09 2012-07-04 丽珠集团丽珠制药厂 Voriconazole suppository and preparation method and application thereof
WO2014041378A3 (en) * 2012-09-14 2014-05-30 Cipla Limited Topical pharmaceutical composition comprising tenofovir, an antibacterial agent and,optonally ciclopirox
US10022373B2 (en) 2014-04-11 2018-07-17 Sinotherapeutics Inc. Posaconazole pharmaceutical compositions and preparation methods, uses and pharmaceutical formulations thereof

Also Published As

Publication number Publication date
EP2282777A1 (en) 2011-02-16
MX2010011244A (en) 2010-11-09
CN102006889A (en) 2011-04-06
KR20110003534A (en) 2011-01-12
JP2011518140A (en) 2011-06-23
US20110104262A1 (en) 2011-05-05
CA2721457A1 (en) 2009-10-22
RU2010146482A (en) 2012-05-27
BRPI0907317A2 (en) 2019-08-27
ZA201007309B (en) 2011-06-29
AU2009237478A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
US20110104262A1 (en) Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent
RU2638818C2 (en) Medicinal dosage form, which contains 6'-fluor-(n-methyl-or n,n-dimethyl)-4-phenyl-4,9'-dihydro-3'n-spiro[cyclohexane-1,1'-pyrano[3,4, b]indole]-4-amine for neuropathic pain treatment
EP0762896B1 (en) Tocopherol compositions for delivery of biologically active agents
EP1173178B1 (en) Composition comprising apomorphine and sildenafil and the use thereof for the treatment of erectile dysfunction
JP3240330B2 (en) Pharmaceutical and cosmetic preparations containing salts of colanic acid
US20150005337A1 (en) Transdermal Delivery Of Systemically Active Central Nervous System Drugs
RU2560879C2 (en) Method of preventing sexually transmitted viral diseases, medication, method of obtaining medication, pharmaceutical composition for local application and condom
US20030087885A1 (en) Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
JP2001520999A (en) Treatment of sexual dysfunction in women
MXPA05001886A (en) Pharmaceutical compositions for buccal delivery of pain relief medications.
CN104519867A (en) Pharmaceutical composition
US20030130225A1 (en) Novel methods of treating local fungal and bacterial infections
NZ501321A (en) Nasal Melatonin composition
CA2391968A1 (en) An improved pharmaceutical composition for treating male erectile dysfunction
EP2224904A2 (en) Intravesical compositions with valrubicin for the treatment of bladder cancer
US20080287408A1 (en) Endometriosis treatment
US20240226068A9 (en) Topical Formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for the Treatment of Rheumatoid Arthritis, Melanoma, Squamous Cell Carcinoma, Atopic Dermatitis, and Psoriasis
US20220040138A1 (en) Teriflunomide topical pharmaceutical compositions
WO2023052407A1 (en) Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
CN118317771A (en) Formulations and methods for topical treatment of Mycobacterium ulcerans in Buruli ulcer
WO2010044094A2 (en) A topical composition for the treatment of erectile dysfunction
AU2002335003A1 (en) Concomitant oral and topical administration of anti - infective agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980113498.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09732346

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009237478

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 588532

Country of ref document: NZ

Ref document number: MX/A/2010/011244

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2721457

Country of ref document: CA

Ref document number: 2191/MUMNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011504526

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009237478

Country of ref document: AU

Date of ref document: 20090416

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009732346

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107025651

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010146482

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12988155

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0907317

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101015